HORIBA UK has expanded its clinical chemistry portfolio with the addition of a new test kit for glucose-6-phosphate dehydrogenase (G6PD). HORIBA is now distributing this cell function assay to the UK market following its acquisition of US-based Pointe Scientific in 2021. Used for the quantitative determination of G6PD enzyme activity in blood, the CE marked POINTE™ G6PD Assay Kit combines everything required for undertaking G6PD testing, excluding controls, in a single box. The G6PD reagents and lyse are also available separately, as are G6PD controls (3 x 3 levels).
G6PD assays can verify deficiency of glucose-6-phosphate dehydrogenase which is widely prevalent worldwide, with an estimated 500 million people affected by this genetic disorder which causes red blood cells to break down prematurely. This can result in hemolytic anemia when red blood cells are being destroyed faster than the body can replace them, reducing the oxygen levels in an individual’s tissues and organs. Hemolytic crisis in G6PD deficient individuals can be triggered by factors including infections, certain drugs such as antimalarials, and even from eating fava beans.
As a sensitive and accurate quantitative test, the G6PD test manufactured by HORIBA Instruments (formerly Pointe Scientific) provides a specific level of G6PD deficiency severity, and hence risk of hemolytic crisis from triggering factors, in line with World Health Organisation classifications. Also, unlike other G6PD assays, which require 30 minutes of sample preparation steps, the POINTE G6PD assay promises just a single 5-minute lysing step and can be on-board lysed, reducing the time to results for G6PD activity levels in whole blood.